

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

VOLUNTARY ANNOUNCEMENT

OFFICIAL OPERATION OF THE AUTHORISED NETWORK FOR QUANTITATIVE EEG DETECTION IN XIAMEN

This announcement is made by Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) on a voluntary basis to keep shareholders and potential investors of the Company informed of its latest development.

The board of directors of the Company is pleased to announce that the newly authorised network for quantitative EEG detection established by the Company in Xiamen held an opening ceremony on 15 October 2018 and officially put into operation. Pursuant to the regional authorised cooperation agreement entered into between HONGKONG TEDA Biomedical Investment Limited, a wholly-owned subsidiary of the Company, and Jiwen (Xiamen) Data Processing Co., Ltd. (集穩(廈門)數據處理有限公司) (“**Jiwen**”), Jiwen will be entitled to use the quantitative EEG detection-related patents and technologies in Xiamen, China in next five years on a chargeable and exclusive basis.

Through the cooperation with relevant technology research and development teams in the United States, the Company possesses the world's unique quantitative EEG detection and diagnosis technology. The detection scope of such technology covers the general public and the population with mental disease, of which the detection of general public mainly includes children's strengths and talents, quantitative analysis of personality trait and diagnosis of retarded children; while detections of the population with mental disease mainly include diseases such as autism, depression, stroke, senile dementia, severe insomnia, chronic pain, cerebral arteriosclerosis, hypomnesia, bipolar disorder, drug addiction and traumatic syndrome. Featured by safety, objective, quantification and accuracy in its nature, such detection technology is by far the world's leading state-of-the-art EEG detection technology.

By order of the Board

Tianjin TEDA Biomedical Engineering Company Limited

Sun Li

Chairman

Tianjin, the PRC
16 October 2018

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Hao Zhihui; the non-executive directors of the Company are Mr. Cao Aixin, Dr. Li Ximing and Ms. Gai Li; the independent non-executive directors of the Company are Mr. Li Xudong, Mr. Wang Yongkang and Ms. Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

The announcement will remain at the "Latest Company Announcements" page on the GEM website at www.hkgem.com for at least seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.